PAML Introduces Blood Test to Aid in the Early Detection of Lung Cancer
Full Service National Reference Laboratory, PAML, leader in its field, introduces blood test to aid in the early detection of lung cancer.
(PRWEB) February 12, 2013
PAML (Pathology Associates Medical Laboratories, LLC) announced today that it has entered into an agreement with Oncimmune® USA LLC to offer the EarlyCDT®-Lung test. EarlyCDT-Lung is an innovative blood test that aids in the risk assessment and the early detection of lung cancer.
Lung cancer is the leading cause of cancer death among men and women in the United States. It takes the lives of more people each year than colon, breast and prostate cancers combined. Approximately 226,160 new cases of lung cancer were diagnosed in 2012, and 160,340 deaths occurred; over 3 times as many men die of lung cancer as prostate cancer and nearly 2 times as many women die of lung cancer as breast cancer.
The performance and clinical utility of the EarlyCDT-Lung test is supported by 17 peer-reviewed publications. The test has a high specificity (93%), seven times fewer false positives and seven times better positive predictive value (PPV) than CT. Additionally, the test offers>91% accuracy, when considering a population with 2% prevalence of lung cancer (20 lung cancers per thousand).
“Oncimmune is excited to partner with PAML in offering our EarlyCDT-Lung test to their physicians,” said Greg Stanley, Chief Commercial Officer at Oncimmune USA. “We believe that through this relationship with PAML, we can improve the outlook and well-being for many individuals who are at increased risk for developing lung cancer.”
“Our partnership with Oncimmune allows PAML to provide our clients with cutting-edge technology in the fight against cancer,” said Francisco R. Velázquez, M.D., S.M., President and Chief Executive Officer of PAML, LLC and PAML Ventures. “The EarlyCDT-Lung blood test is a huge leap forward in diagnosing this deadly disease at its earliest stages which could improve outcomes for many at-risk individuals. We are thrilled to be able to provide this advanced test to our clients through our partnership with Oncimmune.”
Currently, numerous leading academic institutions, as well as more than 2,000 physicians throughout the United States are offering the test. An audit of clinical data from the first 1,600 patients tested by EarlyCDT-Lung validates its utility to detect early-stage lung cancer and its overall performance. Additionally, the Scottish government is conducting a 10,000-patient randomized clinical trial to validate the economic benefit of the test in screening high-risk patients.
Patient blood samples sent to PAML will be analyzed at Oncimmune´s CLIA-certified laboratory located in DeSoto, Kansas.
About PAML (Pathology Associates Medical Laboratories, LLC)
PAML, a full-service medical reference laboratory located in Spokane, WA, is owned by two of the nation´s largest healthcare systems — Providence Health & Services (PH&S) and Catholic Health Initiatives (CHI). One of the top reference laboratories in the country, PAML is also considered an industry leader in joint venture partnerships with community-based hospitals because of their expertise in developing cutting-edge laboratory management systems, including state-of-the-art automation, and support services. For more information, visit http://www.paml.com.
Oncimmune is a privately funded company located in Nottingham, UK with US headquarters and a CLIA laboratory in metropolitan Kansas City. The company launched a proprietary platform technology for early cancer detection, called EarlyCDT® with the first commercially available test, EarlyCDT®-Lung a blood test to aid in the early detection and risk assessment of lung cancer, released in 2009. The EarlyCDT® platform technology measures autoantibodies (immuno-biomarkers) in blood that form early in carcinogenesis. When the body recognizes something as “non-self,” one of the ways it responds is for the immune system to produce large amounts of antibodies. The immune system does not normally produce antibodies against normal tissue antigens and therefore these immuno-biomarkers to cancer antigens provide high specificity for cancer.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweboncimmune/paml/prweb10414186.htm